Theme |
Chemotherapy for Gastrointestinal Malignancy |
Title |
Development of New Anti-Cancer Agents and Future Direction of Chemotherapy |
Author |
Ichinosuke Hyodo |
Department of Internal Medicine, Department of Clinical Research, National Shikoku Cancer Center |
Author |
Hisao Tajiri |
Department of Internal Medicine, Department of Clinical Research, National Shikoku Cancer Center |
Author |
Tomohiro Nishina |
Department of Internal Medicine, National Shikoku Cancer Center |
Author |
Takashi Terao |
Department of Internal Medicine, National Shikoku Cancer Center |
Author |
Shoushi Hirasaki |
Department of Internal Medicine, National Shikoku Cancer Center |
Author |
Toshihiko Doi |
Department of Internal Medicine, National Shikoku Cancer Center |
Author |
Hisashi Endo |
Department of Internal Medicine, National Shikoku Cancer Center |
Author |
Toshikazu Masumoto |
Department of Internal Medicine, National Shikoku Cancer Center |
[ Summary ] |
The key drugs in the treatment of gastrointestinal cancer are fluoropyrimidines, platinum derivatives, topoisomerase I inhibitors, gemcitabine and recently taxanes. New cytotoxic (oral topotecan, PK1, JM216, Tomudex, DX-8951f, etc.) and cytostatic (IMC-C225, ZD1839, rhuMAb VEGF, SU5416, Marimastat, etc.) anti-cancer agents were discussed here, from the viewpoint of future clinical development and application. |